dexamethasone phosphate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
3920 2392-39-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dexamethasone phosphate
  • dexamethasone sodium phosphate
  • decadron
  • dexamethasone phosphoric acid
An anti-inflammatory 9-fluoro-glucocorticoid
  • Molecular weight: 472.45
  • Formula: C22H30FO8P
  • CLOGP: 0.32
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 141.36
  • ALOGS: -2.21
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 2, 1959 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutrophil count decreased 194.47 15.16 120 10322 45906 50548776
Febrile neutropenia 172.06 15.16 150 10292 97517 50497165
Platelet count decreased 102.95 15.16 115 10327 100611 50494071
Bone marrow failure 99.07 15.16 65 10377 27559 50567123
Interstitial lung disease 96.17 15.16 83 10359 53093 50541589
White blood cell count decreased 72.53 15.16 104 10338 116618 50478064
Hepatic function abnormal 71.53 15.16 57 10385 32624 50562058
Neutropenia 67.06 15.16 114 10328 147851 50446831
Anaphylactic shock 66.40 15.16 45 10397 20110 50574572
Pneumocystis jirovecii pneumonia 53.76 15.16 35 10407 14628 50580054
Pyrexia 51.84 15.16 184 10258 380019 50214663
Acute lymphocytic leukaemia recurrent 50.61 15.16 18 10424 1957 50592725
Colony stimulating factor therapy 50.58 15.16 12 10430 306 50594376
Anaemia 43.13 15.16 132 10310 252324 50342358
Drug ineffective 42.46 15.16 65 10377 819268 49775414
Myelosuppression 41.73 15.16 29 10413 13488 50581194
Thrombocytopenia 38.75 15.16 83 10359 127590 50467092
Aortitis 38.59 15.16 12 10430 860 50593822
Joint swelling 36.57 15.16 4 10438 245282 50349400
Neuropathy peripheral 35.41 15.16 68 10374 96689 50497993
Allergy test positive 33.20 15.16 9 10433 396 50594286
Enterocolitis 32.54 15.16 19 10423 6548 50588134
Decreased appetite 32.37 15.16 103 10339 200820 50393862
Disseminated intravascular coagulation 31.45 15.16 27 10415 17108 50577574
Tumour lysis syndrome 30.39 15.16 19 10423 7402 50587280
Small intestinal perforation 30.14 15.16 11 10431 1287 50593395
Radiation necrosis 29.90 15.16 8 10434 335 50594347
Procedural vomiting 27.47 15.16 8 10434 458 50594224
Alanine aminotransferase increased 27.43 15.16 58 10384 88301 50506381
Product dose omission issue 27.38 15.16 3 10439 183835 50410847
Liver disorder 27.33 15.16 36 10406 37186 50557496
Erythema 27.26 15.16 79 10363 146335 50448347
Neoplasm recurrence 26.90 15.16 12 10430 2357 50592325
Peripheral swelling 26.86 15.16 5 10437 205931 50388751
Neurotoxicity 26.59 15.16 23 10419 14717 50579965
Rheumatoid arthritis 26.24 15.16 5 10437 202545 50392137
Eastern Cooperative Oncology Group performance status worsened 24.99 15.16 8 10434 630 50594052
Central nervous system infection 24.34 15.16 8 10434 685 50593997
Neoplasm progression 24.25 15.16 30 10412 29127 50565555
Gastrointestinal perforation 23.97 15.16 12 10430 3049 50591633
Left ventricular dilatation 23.70 15.16 7 10435 421 50594261
Drug intolerance 23.42 15.16 8 10434 219096 50375586
Brain abscess 23.35 15.16 10 10432 1781 50592901
Stomatitis 23.18 15.16 59 10383 101285 50493397
Disease progression 23.17 15.16 57 10385 95809 50498873
Cytokine release syndrome 23.14 15.16 17 10425 8617 50586065
Sinusitis 22.54 15.16 4 10438 170554 50424128
Arthropathy 22.47 15.16 3 10439 157903 50436779
Chemotherapy 22.44 15.16 9 10433 1360 50593322
Posterior reversible encephalopathy syndrome 22.41 15.16 21 10421 14907 50579775
Anorectal disorder 21.81 15.16 9 10433 1463 50593219
Osteonecrosis of jaw 21.66 15.16 30 10412 32496 50562186
Hydrocephalus 21.50 15.16 13 10429 4775 50589907
Ileus 20.61 15.16 19 10423 13210 50581472
Multiple organ dysfunction syndrome 20.43 15.16 37 10405 50300 50544382
Procedural nausea 20.10 15.16 7 10435 715 50593967
Systemic lupus erythematosus 19.24 15.16 3 10439 140619 50454063
Large intestine perforation 18.40 15.16 14 10428 7480 50587202
Dermatitis acneiform 18.17 15.16 11 10431 4046 50590636
Malignant neoplasm progression 18.07 15.16 42 10400 68082 50526600
Respiratory failure 17.73 15.16 50 10392 91131 50503551
Pancytopenia 17.25 15.16 47 10395 83983 50510699
Drug hypersensitivity 17.06 15.16 16 10426 250994 50343688
Myelopathy 17.05 15.16 9 10433 2552 50592130
Constipation 16.56 15.16 79 10363 185629 50409053
Arteriovenous malformation 16.32 15.16 7 10435 1251 50593431
Weight increased 16.06 15.16 11 10431 201880 50392802
Cerebral infarction 16.02 15.16 21 10421 21583 50573099
Abdominal discomfort 15.47 15.16 15 10427 231626 50363056

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Endophthalmitis 169.25 16.56 56 10580 2792 29561099
Choroiditis 168.48 16.56 44 10592 944 29562947
Neutrophil count decreased 144.59 16.56 122 10514 43445 29520446
Intraocular pressure increased 130.46 16.56 53 10583 4736 29559155
Febrile neutropenia 127.38 16.56 178 10458 112062 29451829
Platelet count decreased 117.25 16.56 165 10471 104507 29459384
Interstitial lung disease 115.32 16.56 122 10514 57596 29506295
White blood cell count decreased 103.22 16.56 138 10498 83224 29480667
Uveitis 97.38 16.56 46 10590 5901 29557990
Eye pain 91.16 16.56 55 10581 11540 29552351
Visual acuity reduced 67.19 16.56 50 10586 14826 29549065
Disseminated intravascular coagulation 62.20 16.56 54 10582 19926 29543965
Decreased appetite 61.92 16.56 151 10485 145191 29418700
Large intestine perforation 52.97 16.56 33 10603 7323 29556568
Neutropenia 52.03 16.56 133 10503 131578 29432313
Pyrexia 46.34 16.56 215 10421 287407 29276484
Bone marrow failure 42.70 16.56 51 10585 27398 29536493
Tumour lysis syndrome 40.16 16.56 36 10600 13848 29550043
Hepatic function abnormal 35.36 16.56 56 10580 39203 29524688
Strongyloidiasis 35.15 16.56 17 10619 2295 29561596
Myelosuppression 33.97 16.56 31 10605 12196 29551695
Hiccups 33.93 16.56 27 10609 8826 29555065
Stomatitis 32.14 16.56 52 10584 37061 29526830
Anaemia 27.10 16.56 143 10493 200808 29363083
Gastrointestinal perforation 26.02 16.56 16 10620 3467 29560424
Drug interaction 24.53 16.56 21 10615 197364 29366527
Capillary nail refill test abnormal 24.53 16.56 5 10631 33 29563858
Anaphylactic shock 24.48 16.56 27 10609 13309 29550582
Paronychia 23.18 16.56 14 10622 2939 29560952
Hypoalbuminaemia 22.71 16.56 23 10613 10282 29553609
Tumour necrosis 22.38 16.56 10 10626 1127 29562764
Dermatitis acneiform 21.58 16.56 17 10619 5474 29558417
Disease progression 21.00 16.56 71 10565 81845 29482046
Drug abuse 18.98 16.56 3 10633 79880 29484011
Malignant neoplasm progression 18.91 16.56 64 10572 73795 29490096
PaO2/FiO2 ratio decreased 18.84 16.56 4 10632 33 29563858
Angle closure glaucoma 18.66 16.56 8 10628 817 29563074
Toxicity to various agents 18.65 16.56 21 10615 173640 29390251
Septic shock 18.54 16.56 57 10579 62503 29501388
Hyperglycaemia 18.27 16.56 39 10597 34248 29529643
Lymphocyte count decreased 18.05 16.56 28 10608 19243 29544648
Periodontitis 17.94 16.56 10 10626 1807 29562084
Uveitis-glaucoma-hyphaema syndrome 17.85 16.56 3 10633 5 29563886
Macular oedema 17.62 16.56 11 10625 2447 29561444
Pulmonary artery thrombosis 17.41 16.56 7 10629 608 29563283
Neoplasm progression 17.37 16.56 27 10609 18585 29545306
Myocardial infarction 17.36 16.56 9 10627 110287 29453604
Fall 17.36 16.56 23 10613 177155 29386736
Blood lactate dehydrogenase increased 16.73 16.56 27 10609 19182 29544709

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutrophil count decreased 287.37 14.74 213 18771 76983 64402765
Febrile neutropenia 281.71 14.74 310 18674 187347 64292401
Platelet count decreased 210.91 14.74 253 18731 167458 64312290
Interstitial lung disease 175.78 14.74 178 18806 97554 64382194
Choroiditis 163.21 14.74 42 18942 1045 64478703
White blood cell count decreased 155.49 14.74 211 18773 157626 64322122
Endophthalmitis 149.07 14.74 57 18927 5308 64474440
Bone marrow failure 132.29 14.74 111 18873 47841 64431907
Intraocular pressure increased 106.46 14.74 51 18933 8251 64471497
Hepatic function abnormal 102.72 14.74 110 18874 64203 64415545
Neutropenia 94.61 14.74 214 18770 239410 64240338
Pyrexia 90.76 14.74 364 18620 558280 63921468
Disseminated intravascular coagulation 89.43 14.74 75 18909 32273 64447475
Decreased appetite 82.27 14.74 224 18760 281065 64198683
Anaphylactic shock 73.06 14.74 65 18919 30263 64449485
Myelosuppression 71.61 14.74 58 18926 23772 64455976
Large intestine perforation 68.57 14.74 44 18940 12560 64467188
Tumour lysis syndrome 68.54 14.74 52 18932 19388 64460360
Uveitis 68.24 14.74 44 18940 12664 64467084
Eye pain 59.33 14.74 59 18925 31566 64448182
Pneumocystis jirovecii pneumonia 58.32 14.74 55 18929 27579 64452169
Visual acuity reduced 55.33 14.74 53 18931 27088 64452660
Colony stimulating factor therapy 54.08 14.74 15 18969 500 64479248
Anaemia 53.67 14.74 237 18747 378443 64101305
Strongyloidiasis 45.85 14.74 21 18963 3069 64476679
Stomatitis 44.39 14.74 99 18885 109506 64370242
Neuropathy peripheral 44.10 14.74 103 18881 117422 64362326
Thrombocytopenia 43.72 14.74 155 18829 223646 64256102
Acute lymphocytic leukaemia recurrent 43.47 14.74 22 18962 4004 64475744
Gastrointestinal perforation 42.66 14.74 24 18960 5400 64474348
Malignant neoplasm progression 42.44 14.74 99 18885 112772 64366976
Joint swelling 41.05 14.74 7 18977 215375 64264373
Enterocolitis 39.85 14.74 31 18953 11987 64467761
Peripheral swelling 37.31 14.74 8 18976 209145 64270603
Hiccups 35.39 14.74 25 18959 8351 64471397
Aortitis 35.32 14.74 13 18971 1088 64478660
Neoplasm progression 34.65 14.74 51 18933 40913 64438835
Drug intolerance 33.92 14.74 7 18977 187985 64291763
Allergy test positive 33.69 14.74 10 18974 426 64479322
Small intestinal perforation 33.53 14.74 16 18968 2564 64477184
Toxicity to various agents 33.02 14.74 35 18949 363478 64116270
Rheumatoid arthritis 32.06 14.74 5 18979 164289 64315459
Septic shock 31.76 14.74 85 18899 105352 64374396
Product dose omission issue 31.72 14.74 9 18975 194738 64285010
Fall 31.72 14.74 46 18938 416780 64062968
Disease progression 31.03 14.74 102 18882 141578 64338170
Posterior reversible encephalopathy syndrome 31.02 14.74 36 18948 22910 64456838
Liver disorder 30.95 14.74 56 18928 53295 64426453
Dermatitis acneiform 30.68 14.74 23 18961 8420 64471328
Tumour necrosis 29.78 14.74 13 18971 1696 64478052
Fatigue 29.58 14.74 117 18867 748613 63731135
Hypoalbuminaemia 29.55 14.74 31 18953 17643 64462105
Alanine aminotransferase increased 29.47 14.74 99 18885 138932 64340816
Overdose 28.66 14.74 6 18978 159560 64320188
Erythema 28.66 14.74 120 18864 186950 64292798
Hyperglycaemia 28.03 14.74 58 18926 60910 64418838
Radiation necrosis 27.34 14.74 8 18976 324 64479424
Paronychia 26.56 14.74 19 18965 6473 64473275
Periodontitis 26.36 14.74 16 18968 4143 64475605
Drug abuse 25.89 14.74 4 18980 132370 64347378
Peritonitis 25.39 14.74 34 18950 24989 64454759
Anorectal disorder 25.12 14.74 12 18972 1927 64477821
Cerebral infarction 24.98 14.74 44 18940 41000 64438748
Blood pressure decreased 24.46 14.74 68 18916 86131 64393617
Drug ineffective 24.11 14.74 147 18837 840100 63639648
Capillary nail refill test abnormal 23.96 14.74 5 18979 47 64479701
Sepsis 23.86 14.74 132 18852 230209 64249539
Neurotoxicity 23 14.74 34 18950 27370 64452378
Myocardial infarction 22.99 14.74 10 18974 165811 64313937
Drug interaction 22.88 14.74 45 18939 362038 64117710
Cytokine release syndrome 22.21 14.74 29 18955 20800 64458948
Blood lactate dehydrogenase increased 22.15 14.74 37 18947 33041 64446707
Aspartate aminotransferase increased 21.69 14.74 81 18903 119707 64360041
Chemotherapy 21.60 14.74 10 18974 1497 64478251
Drug hypersensitivity 21.46 14.74 23 18961 237792 64241956
Gait disturbance 21.43 14.74 12 18972 172143 64307605
Arthralgia 20.85 14.74 64 18920 442196 64037552
Osteonecrosis of jaw 20.84 14.74 40 18944 39785 64439963
Central nervous system infection 20.54 14.74 9 18975 1185 64478563
Pulmonary artery thrombosis 20.45 14.74 9 18975 1197 64478551
Constipation 20.23 14.74 126 18858 229211 64250537
PaO2/FiO2 ratio decreased 19.97 14.74 4 18980 30 64479718
Klebsiella infection 19.93 14.74 22 18962 13259 64466489
Confusional state 19.66 14.74 29 18955 261115 64218633
Myelopathy 19.48 14.74 13 18971 3961 64475787
Macular oedema 19.35 14.74 14 18970 4853 64474895
Brain abscess 18.88 14.74 13 18971 4168 64475580
Weight increased 18.84 14.74 21 18963 213327 64266421
Cytopenia 18.81 14.74 23 18961 15448 64464300
Ileus 18.57 14.74 28 18956 22938 64456810
Anterior chamber flare 18.50 14.74 5 18979 151 64479597
Hypokalaemia 18.50 14.74 78 18906 121825 64357923
Sinusitis 18.41 14.74 10 18974 145918 64333830
Multiple organ dysfunction syndrome 17.88 14.74 68 18916 101345 64378403
Neoplasm recurrence 17.77 14.74 12 18972 3727 64476021
Therapeutic product effect decreased 17.57 14.74 6 18978 115345 64364403
Child-Pugh-Turcotte score abnormal 17.50 14.74 3 18981 8 64479740
Abdominal discomfort 17.16 14.74 17 18967 182305 64297443
Eastern Cooperative Oncology Group performance status worsened 17.02 14.74 8 18976 1240 64478508
Cytomegalovirus chorioretinitis 17.00 14.74 13 18971 4899 64474849
Keratolysis exfoliativa acquired 17.00 14.74 3 18981 10 64479738
Pain 16.80 14.74 95 18889 553416 63926332
Pneumonia 16.77 14.74 244 18740 559332 63920416
Aspergillus infection 16.23 14.74 22 18962 16357 64463391
Musculoskeletal stiffness 16.19 14.74 8 18976 123198 64356550
Chromosomal deletion 15.97 14.74 4 18980 89 64479659
Left ventricular dilatation 15.95 14.74 7 18977 925 64478823
Hydrocephalus 15.80 14.74 15 18969 7576 64472172
Pain in extremity 15.63 14.74 42 18942 303043 64176705
Peripheral sensory neuropathy 15.63 14.74 18 18966 11360 64468388
Pancytopenia 15.41 14.74 83 18901 143226 64336522
Bacteraemia 15.29 14.74 28 18956 26883 64452865
Cerebrovascular accident 15.18 14.74 11 18973 137572 64342176
Respiratory failure 15.12 14.74 90 18894 161093 64318655
Cardiac failure congestive 14.99 14.74 10 18974 130570 64349178
Vomiting 14.84 14.74 236 18748 550881 63928867

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
CHEBI has role CHEBI:63562 glucocorticoid receptor agonists
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000932 Antiemetics
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018931 Antineoplastic Agents, Hormonal
MeSH PA D002491 Central Nervous System Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018373 Peripheral Nervous System Agents
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:35705 immunosuppressive agents
CHEBI has role CHEBI:37962 adrenergic agents
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:78298 environmental contaminants

Drug Use (View source of the data)

None




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Inflammation Indication
Cattle Primary bovine ketosis Indication
Cattle Inflammation Indication
Dogs Inflammation Indication
Horses Inflammation Indication

🐶 Veterinary products

ProductApplicantIngredients
Dex-A-Vet Injection Bimeda Animal Health Limited 1
Dex-A-Vet Injection Bimeda Animal Health Limited 1
Dexamethasone Sodium Phosphate Inj. Cronus Pharma Specialities India Private Limited 1
Dexium-SP Bimeda Animal Health Limited 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.75 acidic
pKa2 6.8 acidic
pKa3 11.06 acidic
pKa4 13.94 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST IC50 9.30 CHEMBL CHEMBL
Mineralocorticoid receptor Nuclear hormone receptor Ki 9.44 CHEMBL
Androgen receptor Nuclear hormone receptor Ki 5.85 CHEMBL
Progesterone receptor Nuclear hormone receptor Ki 6.25 CHEMBL
Androgen receptor Transcription factor Ki 4.79 CHEMBL
Fatty acid-binding protein, liver Unclassified Ki 4.66 CHEMBL
Progesterone receptor Transcription factor Ki 5.52 CHEMBL
Glucocorticoid receptor Transcription factor IC50 7.66 CHEMBL

External reference:

IDSource
4020650 VUID
N0000148296 NUI
D00975 KEGG_DRUG
4017922 VANDF
4017923 VANDF
4020650 VANDF
C0770565 UMLSCUI
CHEBI:4462 CHEBI
CHEBI:41879 CHEBI
DEX PDB_CHEM_ID
CHEMBL1201302 ChEMBL_ID
CHEMBL2021430 ChEMBL_ID
CHEMBL1200637 ChEMBL_ID
C004180 MESH_SUPPLEMENTAL_RECORD_UI
2BP70L44PR UNII
9400 PUBCHEM_CID
5743 PUBCHEM_CID
DB01234 DRUGBANK_ID
227682 RXNORM
3245 MMSL
35380 MMSL
39663 MMSL
4552 MMSL
4554 MMSL
6848 MMSL
776 MMSL
d00206 MMSL
002174 NDDF
002176 NDDF
002177 NDDF
372584003 SNOMEDCT_US
396016009 SNOMEDCT_US
396017000 SNOMEDCT_US
7561000 SNOMEDCT_US
C0011777 UMLSCUI
CHEMBL1530428 ChEMBL_ID
CHEMBL384467 ChEMBL_ID
816 INN_ID
D003907 MESH_DESCRIPTOR_UI
312-93-6 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0404-9841 INJECTION, SOLUTION 4 mg INTRA-ARTICULAR ANDA 12 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0404-9842 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 11 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9843 INJECTION, SOLUTION 4 mg INTRAVENOUS ANDA 9 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0641-0367 INJECTION 10 mg INTRAMUSCULAR ANDA 13 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6145 INJECTION 4 mg INTRA-ARTICULAR ANDA 13 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6146 INJECTION 4 mg INTRA-ARTICULAR ANDA 13 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 11695-1411 SOLUTION/ DROPS 1 mg OPHTHALMIC ANDA 15 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 16590-068 SOLUTION/ DROPS 1 mg OPHTHALMIC ANDA 11 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 21695-847 SOLUTION 1 mg OPHTHALMIC ANDA 18 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 24208-720 SOLUTION/ DROPS 1 mg OPHTHALMIC ANDA 16 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42254-088 SOLUTION/ DROPS 1 mg OPHTHALMIC ANDA 15 sections
Dexamethasone Sodium Phosphate Human Prescription Drug Label 1 50090-0627 INJECTION, SOLUTION 4 mg INTRAMUSCULAR ANDA 12 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-1922 INJECTION, SOLUTION 4 mg INTRA-ARTICULAR ANDA 13 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-2313 INJECTION, SOLUTION 4 mg INTRA-ARTICULAR ANDA 13 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-2313 INJECTION, SOLUTION 4 mg INTRA-ARTICULAR ANDA 13 sections
DEXAMETHASONE SODIUM PHOSPHATE Human Prescription Drug Label 1 50090-3300 INJECTION, SOLUTION 4 mg INTRAVENOUS ANDA 10 sections
DEXAMETHASONE SODIUM PHOSPHATE Human Prescription Drug Label 1 50090-3300 INJECTION, SOLUTION 4 mg INTRAVENOUS ANDA 10 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-3541 INJECTION 10 mg INTRAMUSCULAR ANDA 12 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-4567 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 9 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1297 INJECTION 4 mg SOFT TISSUE ANDA 10 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1343 INJECTION 10 mg INTRAMUSCULAR ANDA 10 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1370 INJECTION, SOLUTION 4 mg INTRAMUSCULAR ANDA 13 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1391 INJECTION, SOLUTION 10 mg INTRAMUSCULAR ANDA 13 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1432 INJECTION, SOLUTION 4 mg INTRAMUSCULAR ANDA 10 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1541 INJECTION 100 mg INTRAMUSCULAR ANDA 10 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 52584-239 INJECTION, SOLUTION 4 mg INTRAVENOUS ANDA 9 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 52584-420 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 11 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 52584-421 INJECTION, SOLUTION 4 mg INTRAVENOUS ANDA 11 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 52584-422 INJECTION, SOLUTION 4 mg INTRA-ARTICULAR ANDA 12 sections
ReadySharp Dexamethasone HUMAN PRESCRIPTION DRUG LABEL 1 53225-3660 INJECTION 10 mg INTRAMUSCULAR ANDA 17 sections